CA2978883A1 - Methods for treating proteinopathies - Google Patents

Methods for treating proteinopathies Download PDF

Info

Publication number
CA2978883A1
CA2978883A1 CA2978883A CA2978883A CA2978883A1 CA 2978883 A1 CA2978883 A1 CA 2978883A1 CA 2978883 A CA2978883 A CA 2978883A CA 2978883 A CA2978883 A CA 2978883A CA 2978883 A1 CA2978883 A1 CA 2978883A1
Authority
CA
Canada
Prior art keywords
compound
disease
subject
pharmaceutically acceptable
proteinopathy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2978883A
Other languages
English (en)
French (fr)
Inventor
Seng H. Cheng
Lamya Shihabuddin
Sergio Pablo SARDI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CA2978883A1 publication Critical patent/CA2978883A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
CA2978883A 2015-03-10 2016-03-09 Methods for treating proteinopathies Abandoned CA2978883A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562131071P 2015-03-10 2015-03-10
US62/131,071 2015-03-10
PCT/US2016/021512 WO2016145046A1 (en) 2015-03-10 2016-03-09 Methods for treating proteinopathies

Publications (1)

Publication Number Publication Date
CA2978883A1 true CA2978883A1 (en) 2016-09-15

Family

ID=55587378

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2978883A Abandoned CA2978883A1 (en) 2015-03-10 2016-03-09 Methods for treating proteinopathies

Country Status (17)

Country Link
US (2) US20180036295A1 (enExample)
EP (2) EP3267983B1 (enExample)
JP (2) JP6990110B2 (enExample)
KR (1) KR20170123329A (enExample)
CN (1) CN107872976A (enExample)
AU (1) AU2016229826A1 (enExample)
CA (1) CA2978883A1 (enExample)
EA (1) EA201791993A1 (enExample)
ES (1) ES2973101T3 (enExample)
HK (1) HK1244217A1 (enExample)
HU (1) HUE065628T2 (enExample)
IL (1) IL254393A0 (enExample)
MX (1) MX2017011598A (enExample)
PL (1) PL3267983T3 (enExample)
PT (1) PT3267983T (enExample)
TW (1) TW201642855A (enExample)
WO (1) WO2016145046A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
SG11201911313YA (en) * 2017-06-19 2020-01-30 Kainos Medicine Inc Modulators of alpha-synuclein
TWI644673B (zh) * 2017-07-27 2018-12-21 百朗克股份有限公司 頭孢曲松的用途
JP7633169B2 (ja) * 2019-02-04 2025-02-19 ジェンザイム・コーポレーション グルコシルセラミドシンターゼ（ｇｃｓ）阻害剤を使用した繊毛病の処置
CN113645969A (zh) * 2019-02-04 2021-11-12 建新公司 用于治疗与溶酶体贮积症相关的症状和病症的方法
AU2020384066B2 (en) * 2019-11-15 2025-10-30 Green Cross Corporation Novel derivatives having 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same
US12083115B2 (en) 2020-02-03 2024-09-10 Genzyme Corporation Methods for treating neurological symptoms associated with lysosomal storage diseases
FI4122923T3 (fi) * 2020-03-17 2025-11-12 Sumitomo Pharma Co Ltd Oksadiatsolijohdannainen
AU2021241530A1 (en) * 2020-03-23 2022-10-20 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
BR112023000798A2 (pt) 2020-07-24 2023-02-07 Genzyme Corp Composições farmacêuticas compreendendo venglustat
KR20230047146A (ko) 2020-07-30 2023-04-06 젠자임 코포레이션 뇌 조직 내 글리코스핑고지질 농도를 감소시키는 방법 및 이를 수반하는 신경퇴행성 질환의 치료 방법
US11773088B2 (en) 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
KR20250106321A (ko) 2022-12-01 2025-07-09 젠자임 코포레이션 강력하거나 중간 수준인 cyp3a4 억제제와 조합한 벤글루스타트

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US195A (en) 1837-05-15 Machine fob cutting and dressing stone
US4683A (en) 1846-08-08 waring and richard e
BE640616A (enExample) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
UA118248C2 (uk) * 2011-03-18 2018-12-26 Джензім Корпорейшн Інгібітори глюкозилцерамідсинтази
JP6061922B2 (ja) * 2011-06-22 2017-01-18 ザ ジェネラル ホスピタル コーポレイション プロテイノパチーの処置方法
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide

Also Published As

Publication number Publication date
EP4349408A3 (en) 2024-06-19
WO2016145046A1 (en) 2016-09-15
PL3267983T3 (pl) 2024-05-13
US20180036295A1 (en) 2018-02-08
EP4349408A2 (en) 2024-04-10
CN107872976A (zh) 2018-04-03
JP7374149B2 (ja) 2023-11-06
IL254393A0 (en) 2017-11-30
PT3267983T (pt) 2024-03-12
JP6990110B2 (ja) 2022-02-10
JP2021119185A (ja) 2021-08-12
US20200197374A1 (en) 2020-06-25
ES2973101T3 (es) 2024-06-18
EP3267983A1 (en) 2018-01-17
EP3267983B1 (en) 2023-12-20
JP2018507886A (ja) 2018-03-22
HK1244217A1 (zh) 2018-08-03
HUE065628T2 (hu) 2024-06-28
EA201791993A1 (ru) 2017-12-29
AU2016229826A1 (en) 2017-10-26
TW201642855A (zh) 2016-12-16
MX2017011598A (es) 2017-12-20
KR20170123329A (ko) 2017-11-07

Similar Documents

Publication Publication Date Title
JP7374149B2 (ja) タンパク質症を処置するための方法
US9522923B2 (en) Selective BACE1 inhibitors
US12286420B2 (en) EAAT2 activators and methods of using thereof
AU2020218185B2 (en) Treatment of ciliopathies using inhibitors of glucosylceramide synthase (GCS)
JP2016522254A (ja) Ｂａｃｅ阻害剤
JP2023512366A (ja) リソソーム蓄積性疾患と関連する神経学的症状を処置するための方法
JP2025072556A (ja) リソソーム蓄積性疾患と関連する症状および障害を処置するための方法
JP2019531318A (ja) Ｄｙｒｋ１阻害剤としてのベンゾチアゾール誘導体
HK40108783A (en) Methods for treating proteinopathies
RU2829786C2 (ru) Способы лечения симптомов и нарушений, ассоциированных с лизосомными болезнями накопления
CN110117301B (zh) 用于防治神经退行性疾病的新化合物及其应用
US20230372313A1 (en) Methods for reducing glycosphingolipid concentration in brain tissue and methods of treatment of neurodegenerative diseases involving the same
US20190152962A1 (en) Cyclopropyl derivatives as ror-gamma modulators
US9938266B2 (en) Selective BACE1 inhibitors
HK40042691B (en) Eaat2 activators and methods of using thereof
HK40042691A (en) Eaat2 activators and methods of using thereof
JP2019530647A (ja) Ｂａｃｅ−１阻害剤と抗ｎ３ｐｇｌｕ ａベータ抗体の併用療法

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20210909

FZDE Discontinued

Effective date: 20210909